Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome

Background: Prostate cancer (PCa) patients with pretreatment prostate-speciic antigen (PSA) >20 ng/ml have a high risk of biochemical and clinical failure and even

High-risk prostate cancer includes advanced clinical stage (> T2), Gleason score 8-10 or PSA level > 20ng/mL.. Men with high-risk prostate cancer experience

Various variables may influence the cancer detection rates and diagnostic yield of prostate biop- sies such as; patient age and race, serum PSA level, prostate volume, biopsy

The aim of our study was to compare the cancer detection rates of normal, asymmetric or suspicious prostate such as nodule in DRE by using TRUS guided prostate biopsy results of

CONCLUSION: Percutaneous cryoablation of the prostate is a safe minimally invasive treatment, but it has poor PSA-free survival outcomes in high-risk prostate cancer

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.. Puech P, Potiron E,

Prostate-specific antigen adjusted for the transition zone volume versus free- to-total prostate-specific antigen ratio in predicting prostate cancer.. Zisman A, Leibovici

After the Prostate Cancer Prevention Trial (PCPT) study showed cancer in at least 15% of patients with PSA < 4 ng/mL, prostate biopsy began to be recommended with lower PSA